Integrative Tumor Board: Recurrent Lymphoma

1. Hoffman R , ed. Follicle-center lymphoma. In: Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1311-1317.

2. The Non-Hodgkin’s Lymphoma Classification Project . National Cancer Institute-sponsored study of classification of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.

3. Solal-Celigny . International prognostic index (PI) for follicular lymphomas (FL) [abstract 1121]. Annual meeting of the American Society of Clinical Oncology. Proc ASCO. 2002;21:281a.

4. Gallagher CJ , Gregory WM , Jones AE , et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470-1480.

5. Solal-Celigny P , Brice P , Brousse N , et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1996;14:514-519.

6. Young RC , Johnson RE , Canellos GP , et al. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep. 1977;61:1153-1159.

7. Czuczman MS , et al. NCCN NHL Clinical Practice Guidelines—2004. Paper presented at: NCCN 9th Annual Conference; March 10-14, 2004; Hollywood, Fla.

8. Czuczman M , Grillo-Lopez AJ , LoBuglioet AI , et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission [abstract 1493]. Presented at: American Society of Hematology 45th Annual Meeting and Exposition; December 6-9, 2003; San Diego, Calif.

9. Marcus R , Imrie K , Belch A , et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma [abstract 87]. Presented at: American Society of Hematology 45th Annual Meeting and Exposition; December 6-9, 2003; San Diego, Calif.

10. Hiddeman W. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract 352]. Presented at: American Society of Hematology 45th Annual Meeting and Exposition; December 6-9, 2003; San Diego, Calif.

11. McLaughlin P , Hagemeister FB , Romaguera JE , et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14: 1262-1268.

12. Dean RM , Bishop MR. Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. 2004;4:238-249.

13. Witzig TE , Gordon LI , Cabanillas F , et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453-2463.

14. Kaminski MS , Estes J , Zasadny KR , et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin’s lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.

15. Gregory SA. The roadmap to follicular lymphoma—section 1: chemotherapy options. Paper presented at: Annual meeting of the American Society of Hematology; December 6-9, 2003; San Diego, Calif.